Keyphrases
Placebo-controlled Study
100%
Type 2 Diabetes Mellitus (T2DM)
100%
Albuminuria
100%
Randomized Controlled Study
100%
Empagliflozin
100%
Semaglutide
100%
Albumin-to-creatinine Ratio
62%
Placebo
37%
Plasma Renin Activity
37%
Plasma Aldosterone Concentration
37%
Systolic Blood Pressure
25%
Estimated Glomerular Filtration Rate
25%
Confidence Interval
12%
Randomized Placebo-controlled Trial
12%
A1 Receptor
12%
End of Treatment
12%
Once-daily
12%
Hemoglobin A1c (HbA1c)
12%
Glycemic Control
12%
Treatment Group
12%
Combined Treatment
12%
Receptor Agonist
12%
Glucagon-like
12%
Glomerular Filtration Rate
12%
Renin-angiotensin System Inhibitors
12%
Once-weekly
12%
24-hour Blood Pressure
12%
Glycated Hemoglobin A1c
12%
HbA1c Levels
12%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
12%
Agricultural and Biological Sciences
Placebo
100%
Urinary System
100%
Creatinine
100%
Albuminuria
100%
Body Weight
60%
Aldosterone
60%
Glomerular Filtration Rate
60%
Plasma Renin Activity
60%
Systolic Blood Pressure
40%
Endpoints
40%
Confidence Interval
20%
Agonist
20%
Glycemic Control
20%
Blood Pressure
20%
Immunoassay
20%
Glucagon-Like Peptide 1 Receptor
20%
Renin-Angiotensin System
20%
Cotransporter
20%
Pharmacology, Toxicology and Pharmaceutical Science
Placebo-Controlled Study
100%
Non Insulin Dependent Diabetes Mellitus
100%
Albuminuria
100%
Empagliflozin
100%
Semaglutide
100%
Creatinine
62%
Placebo
50%
Renin
50%
Aldosterone
37%
Hemoglobin A1c
25%
Angiotensin
12%
Glucagon Like Peptide 1 Receptor Agonist
12%
Glycosylated Hemoglobin
12%
Sodium Glucose Cotransporter 2 Inhibitor
12%